UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

September 10, 2022 Date of Report (Date of earliest event reported)

CABALETTA BIO, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction of incorporation) 001-39103 (Commission File Number) 82-1685768 (I.R.S. Employer Identification No.)

2929 Arch Street, Suite 600, Philadelphia, PA (Address of principal executive offices)

19104 (Zip Code)

(267) 759-3100

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Derecommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of Each Exchange
Title of Each Class	Symbol(s)	on Which Registered
Common Stock, par value \$0.00001 per share	CABA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 Regulation FD Disclosure.

On September 10, 2022, Cabaletta Bio, Inc. (the "Company") posted to the "Investors & Media" section of the Company's website at *www.cabalettabio.com* an updated corporate presentation providing a corporate overview and updated development plan (the "Corporate Presentation"). A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form8-K is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On September 10, 2022, the Company issued a press release announcing that it presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A4 as well as28-day safety data and DSG3-CAART persistence data through day 29 for cohorts A1 through A5 from the DesCAARTes[™] trial at the 31st European Academy of Dermatology and Venereology (EADV) Congress. A copy of the full text of the press release referenced above is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

- 99.1 Cabaletta Bio, Inc. Corporate Presentation, dated September 10, 2022, furnished herewith.
- 99.2 <u>Press Release issued by the registrant on September 10, 2022.</u>
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CABALETTA BIO, INC.

Date: September 12, 2022

By: <u>/s/ Steven Nichtberger</u> Steven Nichtberger, M.D. President and Chief Executive Officer

Cabaletta Bio®



Corporate Presentation

SEPTEMBER 2022

© 2022 Cabaletta Bio. All rights reserved.

Disclaimer

The following presentation, including any printed or electronic copy of these slides, the talks given by the presents, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "Cabaletta" or the "Company") and is made for informational purposes only. This Presentation hold under any circumstances create an implication that the information ontained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This Presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, and include, but are not limited to, express or implied statements regarding our current beliefs, expectations and assumptions regarding: our business, four plans and strategies for our CAAR T technology and CABA[™] platform; the progress and results of our DesCAARTes[™] Phase 1 trial, including the significance and impact around the clinical and translational data for cohort A4 at the 31st European Association of Dermatology and Venereology Congress; the therapeutic potential and clinical benefits of our produc candidates; the expectation that Cabaletta bio may improve outcomes for patients suffering from muccosal pemphigus vulgaris; our ability to escalate dosing as high as 10 to 15 billion cells in cohort A5m, initiate dosing in a combination cohort or otherwise; Cabaletta bians to implement a pre-treatment regime and the potential ability to escalate dosing as high as 10 to 15 billion cells in cohort A5m. This as the cance of DSG3-CAART class and brance and impact and the the well continume-mediated clearance of DSG3-CAART class and presents and mat

Various risks, uncertainties and assumptions could cause actual results to differ materially from those anticipated or implied in our forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the success, cost, and timing of our product candidate development activities and preclinical studies and chinical trials, risks related to our ability to demonstrate sufficient evidence of safety, efficacy and tolerability in our preclinical studies and chinical trials is of DSG3-CAART and MuSk-CAART. Cabaletta's plans to evaluate additional cohorts in the DescAARTesTM trial, including a cohort implementing a pre-treatment regiment, the risk that signs of biologic activity or persistence may not inform long-term results, the risk that persistence observed with effective CART-19 oncology studies in combination with lymphodepletion is not indicative of, or applicable to, clinical responses in patients with mPV; risks related to clinical trial is a catual of or regulatory gencies' evaluation of regulatory flings and other information related to our product candidates, our ability to retain and recognize the intended incentives conferred by any Orphan Drug Designation and Fast Track Designations, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk that the results of preclinical studies or clinical studies and linical trials and risks related to our product candidate or similar public health crisis. New risks and uncertainties may emerge from time to time, and it is not possible to predictive of ture results of containting hyperters as result of any new information, related so aresult of publicy update or revise any forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be corred. Accordingly, you are cationed not place induce risks and uncertainties, and other information relates and rescance or these of otherwise. Although we believe the expectations reflect

Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases

Cabaletta® overview

Developing highly specific CAAR T products to treat B cell-mediated autoimmune diseases

DesCAARTes[™] trial in patients with mucosal pemphigus vulgaris (mPV) ongoing

- Favorable safety profile for DSG3-CAART with no dose-limiting toxicities (DLTs) in cohorts A1 to A5¹
- DSG3-CAART persistence through day 29 was similar between cohorts A4 and A5 despite a substantial increase in dose²
- One cohort A4 subject with sustained persistence had transient improvement in several efficacy assessments at 3 months post-infusion²
- · Combination sub-study (pre-treatment with IVIg + cyclophosphamide) prioritized to potentially enhance in vivo DSG3-CAART exposure

MusCAARTes[™] trial in patients with MuSK myasthenia gravis on track to initiate in 2022

Circulating anti-MuSK antibody titers may be ~90% lower than anti-DSG3 antibody titers in pemphigus vulgaris^{3,4,5}

Cell therapy pipeline⁶ targeting diseases that affect over 80,000 U.S. patients

Cash runway through 1Q24 with \$96.8M in cash and investments at the end of 2Q22

CRS - Cytokine release syndrome; SAEs - Serious adverse events

Presented at the off-CEDV congress.
 Anothews, Ian, et al. "Muscle-specific receptor tyrosine kinase autoantibodies—a new immunoprecipitation assay." Clinica chimica acta 348.1-2 (2004): 95-99.
 McConville, John, et al. "Detection and characterization of MuSK antibodies in seronegative myasthenia gravis." Annals of neurology 55.4 (2004): 580-584.
 Marino, Mariapaola, et al. "Long-lasting riturimab-induced reduction of specific—but not total—IgG4 in MuSK-positive myasthenia gravis." Frontiers in immunology 11 (2020): 613.

6. Includes five disclosed product candidates and two undisclosed pipeline disease targets in our pipeline


Cabaletta Bio®

4

^{1.} One subject in cohort A5 developed Grade 1 CRS several hours after each of the 2 infusions which resolved within 2 days (related SAEs). The events were not considered to be DLTs and did not delay study progression 2. Presented at the 31st EADV Congress.


Our scientific platform leverages clinically validated CAR T technology

CAAR T product candidates are designed for selective and specific elimination of the pathogenic B cells



Cabaletta: Advancing targeted cell therapy to autoimmunity

Foundational CAR T technology clinically validated in treating B cell-mediated cancers




Note: Landscape for illustrative purposes only.

Modular platform with "plug-and-play" architecture

CABA™ platform designed to enable a portfolio of programs targeting B cell-mediated diseases

Swapping the extracellular domain, or autoantigen, creates new product candidates



Clinically validated engineered T cell platform is the foundational technology

Pipeline¹ includes multiple disease targets where cure is possible

Therapeutic Area	Indication	Program	Discovery ²	Preclinical	Phase 1	Phase 2/3
6	Mucosal Pemphigus Vulgaris	DSG3-CAART				
Dermatology	Mucocutaneous Pemphigus Vulgaris	DSG3/1-CAART				
Neurology	MuSK Myasthenia Gravis	MuSK-CAART				
Cys Nephrology	PLA2R Membranous Nephropathy	PLA2R-CAART				
Hematology	Hemophilia A w/ FVIII Alloantibodies	FVIII-CAART				


Current pipeline includes 7 programs targeting diseases affecting >80,000 patients in the U.S.

1. Two additional undisclosed disease targets currently in discovery stage are not shown in our pipeline portfolio. 2. In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.

DSG3-CAART for patients with mucosal pemphigus vulgaris

Overview of pemphigus vulgaris

Current treatments require broad immunosuppression associated with safety risks and transient efficacy



CROT = 8+ weeks without lesions while off systemic therapy


1. Image credit: D@nderm

 1. Image credit: D@nderm.
 ~ 1.97% Infettime fitsk Of 12. http://www.yrgd.org/archive/cases/2004/pv/DSCN4996%20copy.JPG
 3. Joly, Pascal, et al. "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial." The Lancet 389.10083 (2017): 2031-2040.
 4. Werth, Victoria P., et al. "Fittximab versus Mycophenolate Mofetti in Patients with Pemphigus Vulgaris." New England Journal of Medicine (2021).
 5. Rituximab tabel, 08/2020 revision.
 6. Kushner, Carolyn J., et al. "Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus." JAMA dermatology (2019).
 7. Tony, Hans-Peter, et al. "Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)." Arthritis research & therapy 13.3 (2011): 1-14. Cabaletta Bio* 10

~1.9% lifetime risk of fatal infection⁷

DSG3-CAART is designed to bind all known pathogenic autoantibodies


Inclusion of all disease-relevant epitopes enables a 'one-size-fits-all' approach for patients with mPV



Ohyama, Bungo, et al. "Epitope spreading is rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2–based swapped molecules." Journal of investigative dermatology 132.4 (2012): 1158-1168.
 Antibodies that target the specific extracellular domain are shown below each extracellular domain.
 Amagai, Masayuki, et al. "Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic." The Journal of clinical investigation 90.3 (1992): 919-926.

DesCAARTes[™] Phase 1 study of DSG3-CAART¹

Evaluating DSG3-CAART as monotherapy & in combination with cyclophosphamide and IVIg



prednisone tapered to low dose prior to infusion

1. FDA has requested, and the Company has agreed, that we will share data from part A to inform a discussion on the optimal design of part C. According to FDA advice, the submission of part A data is not gating to planned enrollment in part B.
2. Cohort A6m reflects a two-dose regimen of 5.0 to 7.5 billion cells, 3 weeks apart, for a total of 10 to 15 billion cells, which is designed to prolong exposure time of DSG3-CAART *in vivo*.
3. Combination cohort reflects a cell dose of 2.5 billion cells, in addition to pre-treatment with intravenous immunoglobulin (IVIg) and cyclophosphamide prior to DSG3-CAART infusion.
4. Combination cohort has been prioritized relative to A6m based on emerging data in cohorts A4 and A5. This is subject to the the protocol.
4. Combination cohort A5.0 to 7.5B and 10B to 15B refers to the number of DSG3-CAART cells infused for patients in dosing cohorts A1 to A6m (M – millions; B – billions).


12

Orphan Drug Designation

Fast Track Designation

DesCAARTes[™] clinical trial assessments & current timeframes

Safety assessed acutely, at 28 days & at 3 months, with data on biologic activity within 6 months**




For the combination conort, patients will be pre-treated with IVIG and cyclophosphamide prior to DSG3-CARKT influsion. ** Clearance of 28-day observation window without DLTs required to initiate next dosing cohort. DLTs include any grade 3 or 4 CRS or neurotoxicity, or any Grade 2 CRS or neurotoxicity that failed to improve to ≤ Grade 1 or baseline within 7 days.

- **For the combination cohort, we believe data on biologic activity up to 9 months may be required to appropriately assess signals of biologic activity.
- This information represents data that we believe can be used to inform potential efficacy endpoints in future clinical development.
 Spindler, Volker, et al. "Mechanisms causing loss of keratinocyte cohesion in pemphigus." Journal of Investigative Dermatology 138.1 (2018): 32-37.

No DLTs observed in first 5 cohorts of DesCAARTes™ trial


Favorable safety profile at all reported doses of DSG3-CAART, including up to 7.5B cell dose cohort



* 20M, 100M, 500M, 2.5B, 5.0B to 7.5B and 10B to 15B refers to the number of DSG3-CAART cells infused for patients in dosing cohorts A1 to A6m (M – millions; B – billions).
** For the combination cohort, we believe data on biologic activity up to 9 months may be required to appropriately assess signals of biologic activity.
*** A 4th subject was dosed in Cohort A5 to generate additional data.

DSG3-CAART persistence through day 29 in cohorts A1 to A5

Dose dependent persistence observed through cohort A4, but leveling off with cohort A5



DSG3-CAART persistence in cohorts A4 & A5 approached lower end of the range seen with CD19-CART^{1,2,3}; combination cohort prioritized to potentially further increase DSG3-CAART exposure


1. Mueller, Karen Thudium, et al. "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia." Blood, The Journal of the American Society

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980

3. The range of persistence observed with anti-CD19 CART therapy in oncology has not been confirmed to be necessary or sufficient for clinical responses in patients with mPV. 4. For cohort A4, 3 month DSG3-CAART persistence data also shown as presented at the 31st EADV Congress. Cabaletta Bio® 15 * A1-1-R refers to a subject in cohort A1 who was retreated at the cohort A3 dose (500 million cells).


Anti-DSG3 antibody levels across cohorts A1-A4

Antibody levels as measured via ELISA generally stable, though patient A4-2 had transient response



Data on Subject A4-2 (2.5x10⁹ DSG3-CAART Dose)

Transient improvement in disease activity by 3 months & steroid taper during that period



Disease Activity Measure	Screen	Pre- Infusion	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
PDAI	1	1 (PR	1	1	0	0	RD 8	0
ODSS ¹	10	5	5	6	Q	0	26	1

1. Oral Disease Severity Score

Strategy and rationale for planned cohorts in DesCAARTes[™] trial

Combo sub-study prioritized to potentially overcome possible cytokine & autoantibody effects on CAART activity


Combination sub-study cohort A4 dose (2.5x10° cells) + cyclophosphamide & IVIg	 Dose-dependent increase in DSG3-CAART persistence through cohort A4 that leveled off with cohort A5 Cyclophosphamide (CY) reduces 'cytokine sink,' potentially enhancing DSG3-CAART activation & proliferation Potential reduction in anti-DSG3 autoantibodies that may inhibit or reduce DSG3-CAART activity CY & IVIg likely to provide transient disease improvement limited to the first few months after infusion^{1,2,3,4,5} Evaluation up to 9 months post-infusion may be required to assess independent DSG3-CAART clinical effect

Cohort A6m · Two A5 infusions 3 weeks apart to potentially increase the duration of maximal exposure to DSG3-CAART 2x A5 dose (1-1.5x1010 cells)

 Amagai, Masayuki, et al. "A randomized double-blind trial of intravenous immunoglobulin for pemphigus." Journal of the American Academy of Dermatology 60.4 (2009): 595-603.
 Arnold, D. F., et al. "An 'n-of-1'placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris." British Journal of Dermatology 160.5 (2009): 1098-1102.
 Zhang, Wenjing, et al. "Short-Term Intravenous Infusion of Cyclophosphamide in the Treatement of Refractory Pemphigus." A Retrospective Study." Dermatology 237.2 (2021): 185-190.
 Heischli, Mary E., Rachel H. Valek, and Amit G. Pandya. "Pulse intravenous cyclophosphamide therapy in pemphigus." Archives of dermatology 135.1 (1999): 57-61.
 Lolis, Margarita, et al. "Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies." Journal of the American Academy of Dermatology 64.3 (2011): 484-489. Cabaletta Bio® 18

Optimizing DSG3-CAART product and patient profiles

Range of strategies being implemented and/or under consideration to increase in vivo activity of DSG3-CAART




1. Combination strategies reflect regimens that include preconditioning and/or immunomodulatory medications prior to administration of DSG3-CAART.

MuSK-CAART for patients with MuSK myasthenia gravis

High unmet need in MuSK myasthenia gravis; a valuable CAAR target

All known extracellular domains can be included in the CAAR design




1. Hain, Berit, et al. "Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab." Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine 33.4 (2006): 575-580.

2. Illa, Isabel, et al. "Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients." Journal of neuroimmunology 201 (2008): 90-94.

Ilia, Isabel, et al. "Sustained response to Kituximab in anti-Aurix and anti-Musk positive Myasthenia Gravis patients." Journal of neuroimmunology 201 (2008): 90-94.
 Jiang, Ruoyi, et al. "Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses." 2(1) insight 5.14 (2020).
 Mathews, Ian, et al. "Muscle-specific receptor tyrosine kinase autoantibodies—a new immunoprecipitation assay." Clinica chimica acta 348.1-2 (2004): 95-99.
 McConville, John, et al. "Detection and characterization of MuSK antibodies in seronegative myasthenia gravis." Annals of neurology 55.4 (2004): 580-584.
 Marino, Mariapaola, et al. "Long-lasting rituximab-induced reduction of specific—but not total—IgG4 in MuSK-positive myasthenia gravis." Frontiers in immunology 11 (2020): 613.

MuSK-CAART demonstrated specific in vivo target engagement¹

MuSK-CAART eliminated anti-MuSK target cells² in an animal model where CART19 cells were a positive control



MuSK-CAART IND open; planning to initiate first-in-human MuSK-CAART trial in 2022

1. https://cabalettabio.com/technology/posters-publications: recently presented at AAI Immunology 2022, MGFA International and ASGCT 2022 conferences in May 2022. 2. Target cells represent a B cell tumor line (CD19 positive) that has been modified to express the anti-MuSK antibody.

MusCAARTes[™] study of MuSK-CAART



Strategy for upcoming trial evaluating MuSK-CAART informed by learnings from DesCAARTes™ study

Open-label study to determine the maximum tolerated dose & to evaluate safety of MuSK-CAART

Major Inclusion Criteria • Age: ≥18	SCREENING MAN		MONITORING (2-4 WEEKS)	Next Patient
MG severity Class I-IVa	25x higher than	Part	Cohort	# Subjects
 MGC ≥ 4 Anti-MuSK antibody positive Negative anti-AChR antibody test 	DesCAARTes™ starting dose	A – Dose Escalation ¹ Increasing dose levels with 2 (+4) design (A1 - 500M, A2 - 2.5B; A32 - 7.5B)	A1-A3	2 (+4) per cohort
Major Exclusion Criteria Prednisone > 0.25-0.5 mg/kg/day 	Combination cohorts based on DesCAARTes™ study 2	A – Adaptive Combination Cohorts ¹ Combination cohorts, starting at A2 CAART dose $(A^{4^2} - 2.5B + Cyclophosphamidg)$	A4+	2 (+4) per cohort
Other autoimmune disorder requiring immunosuppressive therapies		B – Expansion Expanded subject enrollment at final selected dose	В	~12

Study Endpoint & Objectives

Primary Endpoint: Adverse Events, including DLT

Secondary & Tertiary Objectives: CAAR T expansion/persistence, effect on serum anti-MuSK antibody titer, use of concomitant systemic medications, effect on clinical symptoms, manufacturing success rate

* 500M, 2.5B, 7.5B refers to the number of MuSK-CAART cells infused for patients in dosing cohorts A1 to A3 (M – millions; B – billions). 1. A total of 6 subjects will need to have received the final selected dose in Part A of the study. 2. Cohorts A3 and A4 will be enrolled concurrently after cohort A2 is well-tolerated with a preference for enrollment into A4.


PLA2R-CAART for patients with PLA2R-associated membranous nephropathy

Preclinical stage CAART program in membranous nephropathy

Primary MN is an immune-mediated kidney disease with anti-PLA2R antibodies in ~75% of patients

Accumulating evidence of a correlation between PLA2R antibodies and disease activity, remission and relapse in primary MN

- PLA2R autoantibody levels routinely used as diagnostic and prognostic markers
- Autoantibody titer shown to rise rapidly before clinical manifestations
- 3 Co-localization of antigen & PLA2R antibodies at site of damage in kidney



PLA2R+ MN is attractive for CAAR development


- Epitopes are well-defined
- IgG4-dominant disease, similar to PV and MuSK MG
- Eligible US population
 prevalence of ~4,000-8,000;
 incidence of ~700-1,400 / yr

PLA2R-CAART showed in vitro antigen-specific cytotoxicity¹

- PLA2R CAARs demonstrated activity in the presence of physiologic levels of anti-PLA2R autoantibodies
- Candidate CAAR contains targets that bind >95% of anti-PLA2R autoantibodies
- · Demonstrated no off-target binding interactions in membrane protein array

1. As presented at the ASN Kidney Week 2021.

Corporate Summary



Manufacturing strategy

Three-stage approach allows for efficient allocation of capital while leveraging experienced partners

Stage 1: Penn ¹	Stage 2: CDMOs & CABA Process	Stage 3: Cabaletta Facility Commercialization & Scale-Up
2019 –	2021 -	Data-gated, staged investment
Children's Hospital	OxfordBioMedica	Cabaletta Bio°
 Cell processing capacity secured through Penn partnership SOPs previously used to develop an FDA approved product 	 CDMOs for vector and cell processing with commercial support capabilities 	 Leasing followed by engineering and build out of Cabaletta-owned manufacturing facility
Clinical vector validated		

1. Penn-sponsored CD19 CAR IND CMC data has been cross-referenced in DSG3-CAART IND to provide additional data reflecting alignment; cross reference not required for MuSK-CAART IND.

Multiple potential data catalysts with possible pipeline read-through

DesCAARTes[™] trial: Prioritizing combination cohort to potentially enhance DSG3-CAART *in vivo* exposure

- 31st EADV Congress: 6 month clinical & translational data for cohort A4 and 1 month safety & persistence data for cohort A5
 - DSG3-CAART persistence through day 29 was similar between cohorts A4 and A5 despite a substantial increase in dose
 - · One subject in cohort A4 with sustained persistence demonstrated transient improvement in several efficacy assessments at 3 months
- Combination cohort (pre-treatment with IVIg + cyclophosphamide) to potentially enhance in vivo DSG3-CAART exposure

MuSK-CAART: IND cleared within routine 30-day period; received FDA Fast Track Designation

- Circulating anti-MuSK antibody titers may be ~90% lower than anti-DSG3 antibody titers in pemphigus vulgaris^{2,3,4}
- 500M MuSK-CAART cells is planned initial dose (25x higher compared to starting dose in DesCAARTes[™] trial)

Cash runway through 1Q24 with \$96.8M in cash and investments at the end of 2Q22

Multiple anticipated near-term milestones for the pipeline

- DesCAARTes™ Trial: Initial combination sub-study cohort data to be presented at a scientific or medical meeting in 1Q231
 - 1 month safety and DSG3-CAART persistence data
- MuSK-CAART: On track to initiate first-in-human trial in 2022

1. Assumes no dose-limiting toxicities are observed in the cohort, uninterrupted enrollment and no delays due to COVID-19 resurgence occur in the trial.

2. Matthews, Ian, et al. "Muscle-specific receptor tyrosine kinase autoantibodies—a new immunoprecipitation assay." Clinica chimica acta 348.1-2 (2004): 95-99.

3. McConville, John, et al. "Detection and characterization of MuSK antibodies in seronegative myasthenia gravis." Annals of neurology 55.4 (2004): 580-584. 4. Marino, Mariapaola, et al. "Long-lasting rituximab-induced reduction of specific—but not total—IgG4 in MuSK-positive myasthenia gravis." Frontiers in immunology 11 (2020): 613.

* 20M, 100M, 500M, 2.5B, 5.0B to 7.5B and 10B to 15B refers to the number of DSG3-CAART cells infused for patients in dosing cohorts A1 to A6m (M - millions; B - billions).

Cabaletta Bio®

Corporate Presentation

SEPTEMBER 2022

© 2022 Cabaletta Bio. All rights reserved.

Cabaletta Bio°

Cabaletta Bio Presents New Interim Data from the DesCAARTes[™] Phase 1 Trial at the 31st EADV Congress

PHILADELPHIA, Sept. 10, 2022 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A4 as well as28-day safety data and DSG3-CAART persistence data through day 29 for cohorts A1 through A5 from the DesCAARTes[™] trial at the 31st European Academy of Dermatology and Venereology (EADV) Congress, which is being held in Milan, Italy from September 7-10, 2022.

"The new data continue to support the favorable safety profile of DSG3-CAART, with no dose-limiting toxicities, and one grade 1 cytokine release syndrome through cohort A5, at a dose of up to 7.5 billion DSG3-CAART cells. No clear trends in antibody levels or disease activity reduction were observed, though one subject in cohort A4 had no disease activity by three months post-infusion while reducing steroid usage during that period, an antibody titer that dropped more than 20% by three months post-infusion, and was the only patient in the first four cohorts that had detectable DSG3-CAART persistence at the 3 month time point following initial DSG3-CAART infusion," said David J. Chang, M.D., Chief Medical Officer of Cabaletta. "The 2 to 3 fold increase in infusion dose in cohort A5 relative to cohort A4 did not result in a dose-dependent increase in one month DSG3-CAART persistence, suggesting strategies beyond single dose escalation may be required to potentially further increase DSG3-CAART in vivo exposure and generate durable clinical responses. We believe these data support a multiple infusion approach, and provide a rationale to prioritize the combination sub-study, which will employ pre-treatment with intravenous immunoglobulin and cyclophosphamide to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART."

The updated interim data included 16 treated subjects, four cohorts with three patients per cohort and one cohort with four patients, with twelve having completed six months of follow-up after DSG3-CAART infusion, and four having completed 28-day follow-up after DSG3-CAART infusion. The presentation is available on the Company's website at https://www.cabalettabio.com/technology/posters-publications. The data demonstrate:

- Doses up to 7.5 billion DSG3-CAART cells (cohort A5) were generally well tolerated, with no DLTs, and one grade 1 CRS.
- There was a dose-dependent increase in DSG3-CAART persistence through day 29 in cohorts A1 to A4. DSG3-CAART persistence through day 29 in cohort A5 was similar to that observed in cohort A4.
- In cohorts A1 to A4:

- Through six months post DSG3-CAART infusion, no clear pattern was observed in changes in anti-DSG3 Ab levels (ELISA) or disease activity (PDAI) through cohort A4.
- One subject in cohort A4 demonstrated a transient improvement in several assessments of efficacy, including DSG3-CAART persistence at 3 months, decrease of anti-DSG3 Ab levels >20% at 2- and 3-months post-infusion, improvement in PDAI score, and decreased steroid usage.

The rationale for prioritization of the next planned dosing cohorts is as follows:

- Combination sub-study: A4 dose (2.5x10⁹ cells) combined with cyclophosphamide (CY) and intravenous immunoglobulin (IVIg) pre-treatment has been prioritized based on leveling off of DSG3-CAART persistence through day 29 from cohorts A4 to A5.
 - CY may reduce cells that compete for cytokines necessary for DSG3-CAART activation & proliferation.
 - This combination is designed to reduce anti-DSG3 autoantibodies, which may block DSG3-CAART.
 - CY may reduce pathogenic autoantibody-secreting B cells.
 - IVIg may facilitate this reduction through several mechanisms, including binding and blocking the autoantibodies.
- Cohort A6m: 2-fold higher than A5 dose (1-1.5x10¹⁰ cells): Two A5 infusions will be administered 3 weeks apart to potentially increase the duration of *in vivo* exposure and persistence of DSG3-CAART.

The trial is currently being conducted across multiple clinical sites throughout the United States and is enrolling patients in the combinationsub-study. If no DLTs are observed, 28-day safety and persistence data through day 29 for the combinationsub-study cohort are anticipated to be shared at a scientific or medical meeting during the first quarter of 2023.

About the DesCAARTes Phase 1 Trial

Cabaletta's DesCAARTes[™] Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV). The trial is designed to determine the maximum tolerated dose of DSG3-CAART in adult subjects with active, anti-DSG3 Ab positive, biopsy confirmed mPV that is inadequately managed by one or more standard therapies. The primary endpoint is incidence of adverse events (AEs), including dose-limiting toxicities (DLTs), such as certain events of cytokine release syndrome (CRS) and neurotoxicity, related to DSG3-CAART within three months of infusion. Secondary endpoints include CAART persistence (qPCR), anti-DSG3 Ab levels (ELISA) and disease activity (PDAI).

About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA[™] platform, in combination with Cabaletta Bio's proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio's headquarters are located in Philadelphia, PA. For more information, visit<u>www.cabalettabio.com</u> and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains "forward-looking statements" of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding expectations regarding: the company's business plans and objectives; the progress and results of its DesCAARTes[™] Phase 1 trial, including Cabaletta's ability to enroll the requisite number of patients, dose each dosing cohort in the intended manner, and progress the trial; the expected significance and impact around the clinical and translational data updates provided at the scientific meeting described herein and the expected timing and significance around additional clinical data updates from the DesCAARTes™ trial at additional scientific meetings throughout 2022 and 2023; the expectation that Cabaletta may improve outcomes for patients suffering from mPV; Cabaletta's ability to escalate dosing as high as 10 to 15 billion cells in a planned future cohort, initiate dosing in a combination cohort or otherwise; Cabaletta's plans to implement a pre-treatment regimen and the potential ability to enhance in vivo DSG3-CAART exposure; Cabaletta's ability to advance dose escalation in the DesCAARTesTM Phase 1 trial at the current dose ranges for the current cohorts and any projected potential dose ranges for future cohorts, and to optimize its targeted cell therapy; Cabaletta's ability to evaluate, and the potential significance of, the relationship between DSG3-CAART persistence and potential clinical responses in patients with mPV; expectations regarding the design, implementation, timing and success of its current and planned clinical trials and the successful completion of nonclinical studies; planned potential timing and advancement of its preclinical studies and clinical trials and related regulatory submissions; ability to optimize the impact of its collaborations on its development programs; the impact of COVID-19 on the timing, progress, interpretability of data, and results of ongoing or planned preclinical and clinical trials; statements regarding the timing of regulatory filings regarding its development programs; the ability to accelerate Cabaletta's pipeline and develop meaningful therapies for patients, including in collaboration with academic and industry partners; and the anticipated contribution of the members of Cabaletta's executives to the company's operations and progress.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that signs of biologic activity or persistence may not inform long-term results; Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of DSG3-CAART; Cabaletta's plans to evaluate additional cohorts in the DesCAARTes[™] trial, including a cohort implementing apre-treatment regimen; the risk that persistence observed with effective CART-19 oncology studies in combination with lymphodepletion is not indicative of, or applicable to, clinical responses in patients with mPV; risks related to clinical trial site activation or enrollment rates that are lower than expected; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to the impact of public health epidemics affecting countries or regions in which Cabaletta has operations or does business, such as COVID-19; Cabaletta's ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and Fast Track Designation for

DSG3-CAART for the treatment of pemphigus vulgaris; risks related to Cabaletta's ability to protect and maintain its intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Cabaletta's product candidates will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Cabaletta's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

Contacts:

Anup Marda Chief Financial Officer investors@cabalettabio.com

Sarah McCabe Stern Investor Relations, Inc. sarah.mccabe@sternir.com